

REMARKS

Claim Amendments and New Claims 49-62

By virtue of this amendment, claims 9-21, 24, 29-93, 99-113, 116 and 118-120 have been canceled, claims 1-8, 22, 23, 25, 27, 114, 115 and 117 have been amended and claims 121-126 have been added. Support for the amendments can be found throughout the specification and originally filed claims.

As new claims 121-126 are drawn to polypeptides, Applicants request that claims 121-126 be examined with the Group I claims.

Restriction Requirement

Responsive to the Restriction Requirement, Applicants elect the claims of Group I (claims 1-8, 22, 23, 25-28, 94-98, 114-117, 121-126), drawn to polypeptide, for prosecution.

Applicants reserve the right to file a continuing application or take such other appropriate action as deemed necessary to protect the non-elected inventions.

Responsive to the requirement to elect a species, Applicants elect the polypeptide comprising a SARS virus Spike (S) polypeptide and fragments thereof. Claims 1-8, 22, 23, 25-28, 94-98, 114, 115, 117 and 121-126 are readable on the elected species.

Respectfully submitted,

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

By: 

Helen Lee

Registration No. 39,270

Telephone: (510) 923-2192

Facsimile: (510) 655-3542

Emeryville, CA 94662-8097

Dated: *9 April 2007*